Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera

This phase 2 REVIVE trial evaluated rusfertide, a hepcidin mimetic, in patients with phlebotomy-dependent polycythemia vera. Rusfertide significantly reduced phlebotomy rates and maintained hematocrit below 45%. In the randomized withdrawal phase, 60% of rusfertide-treated patients met the primary response criteria versus 17% on placebo. The treatment improved symptom burden and showed a favorable safety profile, with no grade 4 or 5 adverse events. Rusfertide may offer a novel therapeutic option for hematocrit control in polycythemia vera.

This phase 2 REVIVE trial evaluated rusfertide, a hepcidin mimetic, in patients with phlebotomy-dependent polycythemia vera. Rusfertide significantly reduced phlebotomy rates and maintained hematocrit below 45%. In the randomized withdrawal phase, 60% of rusfertide-treated patients met the primary response criteria versus 17% on placebo. The treatment improved symptom burden and showed a favorable safety profile, with no grade 4 or 5 adverse events. Rusfertide may offer a novel therapeutic option for hematocrit control in polycythemia vera.